Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3499Neoplasms 2740Prostatic Neoplasms 1583Colorectal Neoplasms 1248Lung Neoplasms 1188Motor Activity 766Head and Neck Neoplasms 621Pancreatic Neoplasms 601Colonic Neoplasms 586Uterine Cervical Neoplasms 567Carcinoma, Non-Small-Cell Lung 560Carcinoma, Hepatocellular 559Rectal Neoplasms 516Stomach Neoplasms 493Brain Neoplasms 438Anxiety Disorders 401Ovarian Neoplasms 399Pain 376Esophageal Neoplasms 347Polycystic Ovary Syndrome 341Neoplasm Metastasis 340Fatigue 324Urinary Bladder Neoplasms 314Precursor Cell Lymphoblastic Leukemia-Lymphoma 303Melanoma 298Depression 286Multiple Myeloma 283Endometrial Neoplasms 263Lymphoma 258Hematologic Neoplasms 251

Interventions

exemestane 1Tamoxifen 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Letrozole 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × OTHER × HR Positive HER2 Negative Advanced Breast Cancer × Clear all
NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
60 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡